Explore the words cloud of the Vacc-iNTS project. It provides you a very rough idea of what is the project "Vacc-iNTS" about.
The following table provides information about the project.
SCLAVO VACCINES ASSOCIATION
|Coordinator Country||Italy [IT]|
|Total cost||0 €|
|EC max contribution||6˙871˙188 € (0%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-10-01 to 2024-09-30|
Take a look of project's partnership.
|1||SCLAVO VACCINES ASSOCIATION||IT (SIENA)||coordinator||1˙152˙311.00|
|2||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||2˙227˙288.00|
|3||GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL||IT (SIENA)||participant||1˙576˙515.00|
|4||THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE||UK (CAMBRIDGE)||participant||545˙942.00|
|5||THE UNIVERSITY OF LIVERPOOL||UK (LIVERPOOL)||participant||432˙034.00|
|6||UNIVERSITA DEGLI STUDI DI SIENA||IT (SIENA)||participant||341˙017.00|
|7||KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI||GH (KUMASI)||participant||194˙226.00|
|8||UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO||BF (OUAGADOUGOU 03)||participant||192˙980.00|
|9||KENYA MEDICAL RESEARCH INSTITUTE||KE (Nairobi)||participant||107˙575.00|
|10||UNIVERSITY OF OTAGO||NZ (DUNEDIN)||participant||50˙000.00|
|11||PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE||BE (ANTWERPEN)||participant||31˙296.00|
|12||MMGH CONSULTING GMBH||CH (ZURICH)||participant||20˙000.00|
Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACC-INTS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VACC-INTS" are provided by the European Opendata Portal: CORDIS opendata.
Global Alliance for Chronic Diseases SecretariatRead More
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in OsteoarthritisRead More